Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to compounds that inhibit the tyrosine kinase activity of growth factor receptors such as HERl , HER2, and HER4 thereby making them useful as anti-cancer agents.
• the compounds are also useful in the treatment of diseases, other than cancer, which are associated with signal transduction pathways operating through growth factor receptors such as HERl, HER2 and HER4.
• RTKs Receptor tyrosine kinases
• the human epidermal growth factor receptor (HER) family consists of four distinct receptor tyrosine kinases referred to HERl, HER2, HER3, and HER4. These kinases are also referred to as erbBl, erbB2, etc. HERl is also commonly referred to as the epidermal growth factor (EGF) receptor. With the exception of HER3, these receptors have intrinsic protein kinase activity that is specific for tyrosine residues of phosphoacceptor proteins.
• the HER kinases are expressed in most epithelial cells as well as tumor cells of epithelial origin. They are also often expressed in tumor cells of mesenchymal origin such as sarcomas or rhabdomyosarcomas. RTKs such as HERl and HER2 are involved in cell proliferation and are associated with diseases such as psoriasis and cancer. Disruption of signal transduction by inhibition of these kinases would have an antiproliferative and therapeutic effect
• the enzymatic activity of receptor tyrosine kinases can be stimulated by either overexpression, or by ligand-mediated dimerization.
• the formation of homodimers as well as heterodimers has been demonstrated for the HER receptor family.
• An example of homodimerization is the dimerization of HERl (EGF receptor) by one of the EGF family of ligands (which includes EGF, transforming growth factor alpha, betacellulin, heparin-binding EGF, and epiregulin).
• EGF transforming growth factor alpha
• betacellulin transforming growth factor alpha
• betacellulin heparin-binding EGF
• epiregulin epiregulin
• Heterodimerization among the four HER receptor kinases can " be " promoted by binding toinembers of the heregulin (also referred to neuregulin) family of ligands.
• the kinase activity of HER2 has been shown to be activated also by virtue of overexpression of the receptor alone in a variety of cell types. Activation of receptor homodimers and heterodimers results in phosphorylation of tyrosine residues on the receptors and on other intracellular proteins.
• MAP kinase microtubule associated protein kinase
• PI3 kinase phosphatidylinositol 3 -kinase
• the compounds of the invention inhibit the tyrosine kinase activity of growth factor receptors such as HERl, HER2, and HER4 and as such, can be used to treat diseases that are associated with signal transduction pathways operating through growth factor receptors.
• growth factor receptors such as HERl, HER2, and HER4
• the compounds of the instant invention can be used as antiproliferatives and anticancer agents. More specifically, the invention comprises a compound of formula I
• R is selected from the group consisting of aryl, substituted aryl, heterocyclo, and - - - - substituted heterocyclo; - - - - - -- - -
• R 1 is selected from the group consisting of alkyl and substituted alkyl
• R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo; or, R 2 may be absent;
• X is selected from the group consisting of a bond, O, S, C(R ) , C(R ) 3 , NR ;
• R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo, and pharmaceutically acceptable salts, prodrugs, enantiomers, diastereomers, and solvates thereof.
• Also provided for is a method for treating proliferative diseases, comprising administering to a warm-blooded species in need thereof, a therapeutically effective amount of a compound of formula I.
• the present invention provides for compounds of formula I, pharmaceutical compositions employing such compounds and for methods of using such compounds. More specifically, the present invention includes compounds of formula I
• R is selected from the group consisting of aryl, substituted aryl, heterocyclo, and substituted heterocyclo;
• R is selected from the group consisting of alkyl and " substituted alkyl;
• R is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo; or, R 2 may be absent;
• X is selected from the group consisting of a bond, O, S, C(R 3 ) 2 , C(R 3 ) 3 , NR 3 ; and
• R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo, and pharmaceutically acceptable salts, prodrugs, enantiomers, diastereomers, and solvates thereof.
• Preferred alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, heterocyclo, and substituted heterocyclo groups for R 2 include, but are not limited to, the following: benzyl, imidazolyl-ethyl, (methyl-imidazolyl)-ethyl, piperidinyl-ethyl, pyridinyl- propyl, pyridinyl-methyl, morpholinyl-ethyl, (methyl-imidazolyl)-methyl, pyridinyl- ethyl, amino- piperidinyl-methyl, 4-amino-l-methyl-piperidin-3-ol, (methyl- piperazinyl)-ethyl, pyridinyl-ethyl, (methyl-piperidinyl)-ethyl, (methyl-imidazolyl)- propyl, (methyl-piperidinyl)-methyl, (methyl-piperazinyl
• Preferred aryl, substituted aryl, heterocyclo, and substituted heterocyclo groups for R include, but are not limited to, the following: oxazolyl, thienyl,-pyridinyl-, thiazolyl, pyrazinyl, and' phenyl, all of which may be suitably substituted with one or more substitutents.
• the invention comprises a compound of formula I wherein R is aryl or substituted aryl and R 1 is a lower alkyl group. In a more preferred embodiment R 1 is methyl or ethyl.
• the invention comprises a compound of formula I wherein X is -O- and R 2 is cycloalkyl, substituted cycloalkyl, heterocyclo or substituted heterocyclo.
• the invention comprises a compound of formula I wherein Ris phenyl or substituted phenyl and R 1 is methyl or ethyl.
• Preferred compounds of the instant invention include the following
• Preferred compounds of the instant invention exhibit IC 0 values of less than
• HERl, HER2 and HER4 assays 5 ⁇ M in one or more of HERl, HER2 and HER4 assays. More preferred are compounds have less than 1 ⁇ M assay activity. Even more preferred are compounds having less than 0.1 ⁇ M assay activity.
• HERG Human Ether-a-go-go Related Gene
• alkyl refers to straight or branched chain unsubstituted hydrocarbon groups of 1 to 20 carbon atoms, preferably 1 to 7 carbon atoms.
• lower alkyl refers to unsubstituted alkyl groups of 1 to 4 carbon atoms.
• substituted alkyl refers to an alkyl group substituted by, for example, one to four substituents, such as, halo, hydroxy, alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or aralkyl; alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thiol, alkylthio, arylthio, aralkylthio, alkylthiono, arylthiono, aralkylthiono, alkylsulfonyl, arylsulfonyl, aralkyl
• halogen refers to fluorine, chlorine, bromine and iodine.
• aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted.
• aralkyl refers to an aryl or a substituted aryl group bonded directly through an alkyl group, such as benzyl.
• substituted aryl refers to an aryl group substituted by, for example, one to four substituents such as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, halo, trifluoromethoxy, frifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, aryloxy, aralkyloxy, a ino, alkylamino, arylamino, aralkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, sulfonic acid, alkys
• heteroaryl refers to an optionally substituted, aromatic group for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom and at least one carbon atom-containing ring, for example, pyridine, tetrazole, indazole.
• alkenyl refers to straight or branched chain hydrocarbon groups of 2 to 20 carbon atoms, preferably 2 to 15 carbon atoms, and most preferably 2 to 8 carbon atoms, having one to four double bonds.
• substituted alkenyl refers to an alkenyl group substituted by, for example, one to two substituents, such as, halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, alkylthiono, alkylsulfonyl, sulfonamido, nitro, cyano, carboxy, carbamyl, substituted carbamyl, guanidino, indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl and the like.
• substituents such as, halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, alkanoylamino, thiol,
• alkynyl refers to straight or branched chain hydrocarbon groups of 2 to 20 carbon atoms, preferably 2 to 15 carbon atoms, and most preferably 2 to 8 carbon atoms, having one to four triple bonds.
• substituted alkynyl refers to an alkynyl group substituted by, for example, a substituent, such as, halo, hydroxy, alkoxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, alkylthiono, alkylsulfonyl, sulfonamido, nitro, cyano, carboxy, carbamyl, substituted carbamyl, guanidino and heterocyclo, e.g. imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl,
• cycloalkyl refers to an optionally substituted, saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C 3 -C carbocylic ring.
• exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloctyl, cyclodecyl, cyclododecyl, and adamantyl.
• substituents include one or more alkyl groups as described above, or one or more groups described above as alkyl substituents.
• heterocycle refers to an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic cyclic group, for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring.
• Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the nitrogen heteroatoms may also optionally be quaternized.
• the heterocyclic group may be attached at any heteroatom or carbon atom.
• exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, homopiperazinyl, 2- oxohomopiperazinyl, 2-oxopyrrolidinyl, 2-oxa
• bicyclic heterocyclic groups include 2,3 -dihydro-2-oxo- 1 H-indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N- oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,l-b]pyridinyl] or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-
• heterocyclo substituents include one or more alkyl or aralkyl groups, as described above, or one or more groups described above as alkyl substituents as well as alkylsulfonyl groups and haloacetyl groups. Also included are smaller heterocyclos, such as, epoxides and aziridines. Preferred substituted heterocycles are shown is the examples of this specification.
• carrier ring refers to stable, saturated or partially unsaturated monocyclic hydrocarbon rings of 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
• carbocyclic ring may be substituted at one or more substitutable ring positions by one or more groups independently selected from alkyl (preferably lower alkyl), alkoxy (preferably lower alkoxy), nitro, monoalkylamino (preferably a lower alkylamino), dialkylamino (preferably a di[lower]alkylamino), cyano, halo, haloalkyl (preferably trifluoromethyl), alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido (preferably lower alkyl amido), alkoxyalkyl (preferably a lower alkoxy[lower]alkyl), alkoxycarbonyl (preferably a lower alkoxycarbonyl), alkylcarbonyloxy (preferably a lower alkylcarbonyloxy) and aryl (preferably phenyl), said aryl (preferably lower alkyl), alkoxy (preferably lower alkoxy), nitro, monoalkylamino
• heteroatoms shall include oxygen, sulfur and nitrogen.
• the compounds of formula I may form salts which are also within the scope of this invention.
• Pharmaceutically acceptable (i.e. non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, e.g., in isolating or purifying the compounds of this invention.
• the compounds of formula I may form salts with alkali metals such as sodium, potassium and lithium, with alkaline earth metals such as calcium and magnesium, with organic bases such as dicyclohexylamine, tributylamine, pyridine and amino acids such as arginine, lysine and the like.
• alkali metals such as sodium, potassium and lithium
• alkaline earth metals such as calcium and magnesium
• organic bases such as dicyclohexylamine, tributylamine, pyridine and amino acids such as arginine, lysine and the like.
• amino acids such as arginine, lysine and the like.
• the compounds for formula I may form salts with a variety of organic and inorganic acids.
• Such salts include those formed with hydrogen chloride, hydrogen bromide, methanesulfonic acid, sulfuric acid, acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid and various others (e.g., nitrates, phosphates, borates, tartrates, citrates, succinates, benzoates, ascorbates, salicylates and the like).
• Such salts can be formed as known to those skilled in the art.
• zwitterions inner salts
• All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
• the definition of compounds according to the invention embraces all the possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity.
• the racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by cbiral column chromatography.
• the individual optical isomers can be obtained from the racemates from the conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
• Compounds of the formula I may also have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., the compound for formulas I) is a prodrug within the scope and spirit of the invention.
• prodrugs are well known in the art.
• prodrug derivatives see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Nol.42, p. 309-396, edited by K. Widder, et al. (Acamedic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krosgaard- Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H.
• solvates e.g., hydrates
• Methods of solvation are generally known in the art.
• the present invention is based on the discovery that certain pyrrolotriazines are inhibitors of protein kinases. More specifically, pyrrolotriazines such as those described in this invention inhibit the protein tyrosine kinase activity of members of the HER family of receptors. These inhibitors will be useful in the treatment of proliferative diseases that are dependent on signaling by one or more of these receptors. Such diseases include psoriasis, rheumatoid arthritis, and solid tumors of the lung, head and neck, breast, colon, ovary, and prostate.
• the invention relates to a pharmaceutical composition of compound of formula I, or pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier in the treatment of hype ⁇ roliferative disorder in mammal.
• the said pharmaceutical composition is expected to inhibit the growth of those primary and recurrent solid tumors which are associated with HERl (EGF receptor) and HER2, especially those tumors which are significantly dependent on HERl or HER2 for their growth and spread, including for example, cancers of the bladder, squamous cell, head, colorectal, oesophageal, gynecological (such as ovarian), pancreas, breast, prostate, vulva, skin, brain, genitourinary tract, lymphatic system (such as thyroid), stomach, larynx and lung.
• the compounds of the present invention are also useful in the treatment of noncancerous disorders such as psoriasis and rheumatoid arthritis.
• noncancerous disorders such as psoriasis and rheumatoid arthritis.
• a compound of the formula I, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiproliferative effect in a warm-blooded animal such as a human being.
• a method for producing an antiproliferative effect in a warm-blooded animal which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined herein before.
• compounds of the present invention can be used for the treatment of proliferative diseases, including psoriasis and cancer.
• the HERl receptor kinase has been shown to be expressed and activated in many solid tumors including head and neck, prostate, non-small cell lung, colorectal, and breast cancer.
• the HER2 receptor kinase has been shown to be overexpressed in breast, ovarian, lung and gastric cancer.
• Monoclonal antibodies that downregulate the abundance of the HER2 receptor or inhibit signaling by the HERl receptor have shown anti-tumor effficacy in preclincal and clinical studies.
• inhibitors of the HERl and HER2 kinases will have efficacy in the treatment of tumors that depend on signaling from either of the two receptors.
• these compounds will have efficacy in inhibiting tumors that rely on HER receptor heterodimer signaling.
• These compounds are expected to have efficacy either as single agent or in combination (simultaneous or sequentially) with other chemotherapeutic agens such as Taxol, adriamycin, and cisplatin.
• HERl and HER2 signaling has been shown to regulate expression of angiogenic factors such as vascular endothelial growth factor (NEGF) and interleukin 8 (IL8)
• NEGF vascular endothelial growth factor
• IL8 interleukin 8
• NEGF vascular endothelial growth factor
• IL8 interleukin 8
• the HER2 receptor has been shown to be involved in the hype ⁇ roliferation of synovial cells in rheumatoid arthritis, and may contribute to the angiogenic component of that inflammatory disease state.
• the inhibitors described in this invention are therefore expected to have efficacy in the treatment of rheumatoid arthritis.
• the ability of these compounds to inhibit HERl further adds to their use as anti-angiogenic agents.
• the antiproliferative treatment defined herein before may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
• the compounds of this invention may also be useful in combination with known anti-cancer and cytotoxic agents and treatments, including radiation. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range.
• Compounds of formula I may be used sequentially with known anticancer or cytotoxic agents and treatment, including radiation when a combination formulation is inappropriate.
• antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example, linomide, inhibitors of integrin ⁇ v ⁇ 3 function, angiostatin, razoxane);
• cytostatic agents such as antiestrogens (for example, tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene), progestogens (for example, megestrol acetate), aromatase inhibitors (for example, anastrozole, letrozole, borazole, exemestane), antihormones, antiprogestogens, antiandrogens (for example, flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example, gosereline acetate, leuprolide), inhibitors of testosterone 5 ⁇ - dihydroreductase (for example, finasteride), farnesyltransferase inhibitors, anti-invasion agents (for example, metalloproteinase inhibitors such as marimastat and inhibitors of urokinase plasm
• the formula I compounds of the present invention are of interest for their antiproliferative effects. Such compounds of the invention are expected to be useful in a wide range of disease states including cancer, psoriasis, and rheumatoid arthritis.
• the compounds of formula I are useful in the treatment of a variety of cancers, including (but not limited to) the following: -carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
• -tumors of mesenchymal origin including fibrosarcoma and rhabdomyosarcoma;
• tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma and schwannomas;
• inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate hype ⁇ lasia, familial adenomatosis polyposis, neuro-fibromatosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation and inflammatory bowel disease
• the compounds of formula I are especially useful in treatment of tumors having a high incidence of tyrosine kinase activity, such as colon, lung, and pancreatic tumors.
• tumors having a high incidence of tyrosine kinase activity such as colon, lung, and pancreatic tumors.
• Compounds of formula I may also be useful in the treatment of diseases other than cancer that may be associated with signal transduction pathways operating through growth factor receptors such as HERl (EGF receptor), HER2, or HER4.
• growth factor receptors such as HERl (EGF receptor), HER2, or HER4.
• compositions of the present invention containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
• Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non- toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
• excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and abso ⁇ tion in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• a water soluble taste masking material such as hydroxypropyl-methylcellulose or hydroxypropyl-cellulose, or a time delay material such as ethyl cellulose, cellulose acetate buryrate may be employed.
• Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
• Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan
• the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
• preservatives for example ethyl, or n- propyl p-hydroxybenzoate
• coloring agents for example ethyl, or n- propyl p-hydroxybenzoate
• flavoring agents such as sucrose, saccharin or aspartame.
• sweetening agents such as sucrose, saccharin or aspartame.
• Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example aracbis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
• the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
• Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
• These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
• Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
• compositions of the invention may also be in the form of an oil-in-water emulsions.
• the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
• Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
• the emulsions may also contain sweetening, flavoring agents, preservatives and antioxidants.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
• the pharmaceutical compositions may be in the form of a sterile injectable aqueous solutions. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
• the sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase.
• the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microernulation.
• the injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound.
• a continuous intravenous delivery device may be utilized.
• An , example of such a device is the Deltec CADD-PLUS.TM. model 5400 intravenous pump.
• the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3 -butane diol.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug.
• These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
• creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed.
• topical application shall include mouth washes and gargles.
• the compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
• the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
• Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
• the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, sex and response of the individual patient, as well as the severity of the patient's symptoms. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent or treatment within its approved dosage range.
• Compounds of formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of formula I may be administered either prior to or after administration of the known anticancer or cytotoxic agent(s).
• the compounds may be administered in a dosage range of about 0.05 to 200 mg/kg/day, preferably less than 100 mg/kg/day, in a single dose or in 2 to 4 divided doses.
• kinase buffer that contained 20 mM Tris.HCl, pH 7.5, 10 mM MnCl 2 , 0.5 mM ditliiothreitol, bovine serum albumin at 0.1 mg/ml, poly(glu/tyr, 4:1) at 0.1 mg/ml, 1 ⁇ M ATP, and 4 ⁇ Ci/ml [ ⁇ - 33 P]ATP.
• Poly(glu/tyr, 4:1) is a synthetic polymer that serves as a phosphoryl acceptor and is purchased from Sigma Chemicals. The kinase reaction is initiated by the addition of enzyme and the reaction mixtures were incubated at 26 °C for 1 h.
• the reaction is terminated by the addition of EDTA to 50 mM and proteins are precipitated by the addition of trichloroacetic acid to 5%.
• the precipitated proteins are recovered by filtration onto Packard Unifilter plates and the amount of radioactivity inco ⁇ orated is measured in a Topcount scintillation counter.
• cytoplasmic sequences of the receptors were expressed in insect cells as GST fusion proteins, which were purified by affinity chromatography.
• the cytoplasmic sequence of HER2 was subcloned into the baculovirus expression vector pBlueBac4 (Invitrogen) and was expressed as an untagged protein in insect cells.
• the recombinant protein was partially purified by ion-exchange chromatography.
• the instant compounds inhibit HERl, HER2, and HER4 kinases with IC 50 values between 0.001 and 25 ⁇ M.
• Preferred compounds have IC 50 values between 0.001 - 5.0 ⁇ M. More preferred compounds have IC 50 values between 0.001 - 1.0 ⁇ M. Most preferred compounds have IC 50 values between 0.001 - 0.1 ⁇ M.
• a HERG potassium channel assay may be used to screen compounds for HERG activity (see Caballero R, et al., Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization, Molecular Pharmacology, Vol. 59, No. 4, pp. 825-36, 2001). Accordingly, preferred compounds have lower HERG assay activity.
• E 1 , E 2 are ester groups and X 1 is a halogen
• the first step of Scheme 1 is accomplished by treatment of a 3 -alkyl- 1H- pyrrole-2,4-dicarboxylic acid ester i (T. D. Lash et al., J. Heterocyclic Chem., 1991, 28, 1671) with a base such as potassium t-butoxide or sodium hydride in an anhydrous solvent such as THF or DMF followed by an aminating reagent, such as O-(2,4- dmifro-phenyl)-hydroxylamine (T. Sheradsky, J. Heterocyclic Chem., 1967, 4, 413) or chloramine (I. P. Sword, J. Chem. Soc. C, 1971, 820) to give the pyrrolylamine ii. Step 2
• the pyrrolylamine ii is heated with excess formamide to give the pyrrolotriazinone iii.
• Compound iii is converted to a 4-halo-pyrrolotriazine iv by heating with the appropriate phosphorus oxyhalide, e.g., the 4-chloro-pyrrolotriazine is obtained by heating iii with phosphorus oxychloride.
• the 4-halo-pyrrolotriazine iv can be converted into compound x as outlined in Scheme 2.
• 5-Nitroindazole v can be alkylated to give indazole vi. This can be accomplished under a variety of conditions, for example, by heating a mixture of v, potassium carbonate, and the appropriate alkylating agent in DMF.
• nitroindazole vi is reduced to the corresponding aminoindazole vii under standard conditions, such as, hydrogenation of vi over 5% platinum on carbon in ethanol.
• the carboxylic acid ester viii can be saponified by treatment with a base such as an aqueous solution of LiOH and then acidified by treatment with an acid such as HCI to give the carboxylic acid ix.
• a base such as an aqueous solution of LiOH
• an acid such as HCI
• Conversion of the carboxylic acid ix to the final product x can be accomplished under a variety of conditions.
• the carboxylic acid ix can be converted to the corresponding isocyanate via Curtius rearrangement by treatment with an appropriate azide such as diphenylphosphorazidate in the presence of a base such as triethylamine.
• the intermediate isocyanate is then trapped with the appropriate nucleophile such as an alcohol or amine to give the corresponding urea or urethane x.
• HPLC Ret Time is the HPLC retention time that was obtained under the following conditions:
• Hypersil C18 BDS column 250 x 4.6 mm, 5 ⁇ m, a detection wavelength of 254 nm, and a flow rate of 1 mL/min.
• YMC column HPLC all gradients started with 100% solvent A (10% MeOH, 90% H 2 O, 0.1% TFA) and ended with 100% solvent B (90% MeOH, 10% H 2 O, 0.1% TFA)], flow rate (mL/min).
• UN detection was always conducted at 220 nM.
• a 500 mL Parr hydrogenator bottle was charged with l-benzyl-5-nitroindazole (30.4 g, 120 mmol), absolute ethanol (240 mL) and 5% platinum on carbon (1.5 g, 50% wet).
• the bottle was placed on a Parr hydrogenation apparatus, the bottle pressurized with hydrogen to 50 psi and the bottle shook until the uptake of hydrogen ceased.
• the contents of the bottle were then transferred to a IL round bottomed flask, warmed to approximately 60 °C under nitrogen and rapidly filtered through a celite pad.
• the filter cake was washed with ethanol (lOOmL). Water (250 mL) was then added to the filtrate and the resulting suspension stirred for 4 hours in an ice bath.
• HPLC Retention Times were determined using a Hypersil BDS C18 column with a 15 minute gradient time.
• HPLC Retention Times were determined using a Hypersil BDS C18 column with a 15 minute gradient time. .
• YMC TurboPack Pro column with a 2 minute gradient.
• 2 YMC S5 ODS column with a 4 minute gradient.
• 4 YMC ODS-A C18 column with a 2 minute gradient.
• 5 YMC C18 S5 column with a 2 minute gradient.
• R 1 methyl
• HPLC Retention Times were determined using a Hypersil BDS C18 column with a 15 minute gradient time.
• HPLC Retention Times were determined using a Hypersil BDS C18 column with a 15 minute gradient time.
• the mixture was cooled from 25 °C to 15 °C, and concentrated HCI was added, 12.2 M in water (0.89 eq), until the pH of the mixture reached 6.5, while maintaining the temperature between 17-22 °C
• the mixture was held for 15 ⁇ 25 hr at 5 °C and then the solids were collected on a filter funnel.
• the filter-cake was washed with two portions of water (1.43 vol) and two portions of heptane (1.43 vol).
• the wet solid was transferred to a drying tray, and dried at 45 °C for 21 h to afford the product.
• the mixture was stirred rapidly for 10 min, and the phases are allowed to separate.
• the organic phase was discarded, and the rich aqueous phase was treated again with heptane (3 vol). After stirring rapidly 10 min, the phases were allowed to settle, and the organic phase was discarded.
• the rich aqueous portion was cooled to -5-0° C and 37 wt% hydrochloric acid (aq) was added while maintaining a batch temperature ⁇ 10° C until pH ⁇ 2.
• the resulting slurry was kept at -10-0° C for a minimum of 4 h.
• the slurry was then filtered and washed with pre-cooled (3-7° C) water (2 x 4.6 vol).
• the wet cake was dried in vacuo at 40-45° C to afford the desired product.
• reaction mixture was cooled from 58 °C to 40 ⁇ 50 °C
• indazole F 0.88 eq
• diisopropylethylamine 1.1 eq
• the reaction was heated to 70-80 °C and held at this temperature until it was shown complete by HPLC. It was then cooled to 55 °C and isopropyl alcohol (15.5 vol) was added.
• the reaction mixture was cooled from 55 °C to 22 °C over a period of 1.8 ⁇ 2.2 hr. and filtered. The filter cake was washed with cold isopropyl alcohol (5.5 vol) and dried under vacuum below 50 °C to afford the product.
• the product rich organic layer was collected and water (10 vol) was added into the mixture at 55-60 °C in 15-30 min. The mixture was held at 55-60 °C for 30 min after addition of water, then cooled to 19-25 °C over 1 h.
• the product was filtered and washed with ethyl acetate (2 x 3 vol).
• the filter cake was reslurried with ethyl acetate (15 vol) and butylhydroxyanisole (2.7 wt %) was added.
• the resulting slurry was distilled at atmospheric pressure.
• the volume of the mixture was adjusted to 8-10 volumes while maintaining the temperature at 74-78 °C
• the temperature was cooled to 19-25 °C over an hour.
• the solid was collected by filtration and the filter cake was rinsed with ethyl acetate (2.2 vol). The solid was dried under vacuum at 45 °C to afford the desired compound.

Priority Applications (15)

Applications Claiming Priority (2)

Publications (2)

Family

ID=32595133

Family Applications (1)

Country Status (27)

Cited By (17)

Families Citing this family (39)

Citations (1)

Family Cites Families (13)

• 2003
  • 2003-12-08 TW TW092134601A patent/TW200420565A/zh unknown
  • 2003-12-12 KR KR1020057010549A patent/KR101073801B1/ko not_active IP Right Cessation
  • 2003-12-12 PT PT03813396T patent/PT1569937E/pt unknown
  • 2003-12-12 AR ARP030104592A patent/AR042450A1/es unknown
  • 2003-12-12 AT AT03813396T patent/ATE534648T1/de active
  • 2003-12-12 PE PE2003001275A patent/PE20040805A1/es not_active Application Discontinuation
  • 2003-12-12 UA UAA200506891A patent/UA80591C2/uk unknown
  • 2003-12-12 CN CNA200380105906XA patent/CN1726216A/zh active Pending
  • 2003-12-12 PL PL377517A patent/PL377517A1/pl not_active Application Discontinuation
  • 2003-12-12 ES ES03813396T patent/ES2374393T3/es not_active Expired - Lifetime
  • 2003-12-12 WO PCT/US2003/039542 patent/WO2004054514A2/en active Application Filing
  • 2003-12-12 RU RU2005120650/04A patent/RU2356903C2/ru not_active IP Right Cessation
  • 2003-12-12 CN CN200910246410A patent/CN101723948A/zh active Pending
  • 2003-12-12 NZ NZ540338A patent/NZ540338A/en not_active IP Right Cessation
  • 2003-12-12 BR BR0316755-0A patent/BR0316755A/pt not_active IP Right Cessation
  • 2003-12-12 AU AU2003300877A patent/AU2003300877B2/en not_active Ceased
  • 2003-12-12 MX MXPA05006164A patent/MXPA05006164A/es active IP Right Grant
  • 2003-12-12 CA CA002509650A patent/CA2509650C/en not_active Expired - Fee Related
  • 2003-12-12 DK DK03813396.3T patent/DK1569937T3/da active
  • 2003-12-12 EP EP03813396A patent/EP1569937B1/en not_active Expired - Lifetime
  • 2003-12-12 JP JP2004560804A patent/JP4511367B2/ja not_active Expired - Fee Related
  • 2003-12-12 RS YUP-2005/0441A patent/RS20050441A/sr unknown
  • 2003-12-15 US US10/736,476 patent/US6916815B2/en not_active Expired - Fee Related
• 2005
  • 2005-06-01 ZA ZA200504507A patent/ZA200504507B/en unknown
  • 2005-06-02 US US11/143,279 patent/US7148220B2/en not_active Expired - Fee Related
  • 2005-06-07 NO NO20052733A patent/NO20052733L/no not_active Application Discontinuation
  • 2005-06-10 HR HR20050535A patent/HRP20050535A2/hr not_active Application Discontinuation
  • 2005-06-10 IS IS7890A patent/IS7890A/is unknown
  • 2005-06-13 CO CO05057043A patent/CO5570660A2/es not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events